Mucosal healing in inflammatory bowel disease - A true paradigm of success?

Maneesh Dave, Edward V. Loftus

Research output: Contribution to journalReview articlepeer-review

99 Scopus citations


Mucosal healing is gaining more acceptance as a measure of disease activity in Crohn's disease and ulcerative colitis, and it is also gaining acceptance as an endpoint in clinical trials. Recent publications have correlated achievement of mucosal healing with good outcomes. Currently, there is no validated definition of what constitutes mucosal healing in inflammatory bowel disease. In clinical trials of ulcerative colitis, mucosal healing has been achieved with 5-aminosalicylates, corticosteroids, azathioprine, and infliximab. For Crohn's disease, mucosal healing has been achieved with corticosteroids, infliximab, and adalimumab, and mucosal healing has been maintained with infliximab. Achievement of long-term mucosal healing has been associated with a decreased risk of colectomy and colorectal cancer in ulcerative colitis patients, a decreased need for corticosteroid treatment in Crohn's disease patients, and a trend toward a decreased need for hospitalization in Crohn's disease patients. Unfortunately, assessment of mucosal healing requires regular use of endoscopy, which is associated with increased costs, patient discomfort, and side effects. Biomarkers such as fecal calprotectin, fecal lactoferrin, serum C-reactive protein, and fecal S100A12 have been shown to correlate with disease activity in ulcerative colitis and Crohn's disease; in the future, these biomarkers might be used as surrogate markers for mucosal healing. Newer clinical trials are incorporating mucosal healing as an endpoint for evaluation of efficacy. However, before mucosal healing will be sufficient to guide therapy, clinicians need a standard definition of mucosal healing and a consistently used, prospectively validated scale with good interobserver agreement.

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalGastroenterology and Hepatology
Issue number1
StatePublished - Jan 2012


  • Anti-tumor necrosis factor agents
  • Colonoscopy
  • Corticosteroids
  • Crohn's disease
  • Mucosal healing
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Mucosal healing in inflammatory bowel disease - A true paradigm of success?'. Together they form a unique fingerprint.

Cite this